128 related articles for article (PubMed ID: 27760596)
1. [Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].
Xing P; Hao X; Hu X; Wang Y; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):670-674. PubMed ID: 27760596
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
3. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of
Advanced Lung Squamous Carcinoma].
Lv Y; Jiang R; Ma C; Li J; Wang B; Sun L; Mu N
Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):500-4. PubMed ID: 26302347
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
Wang J; Li K; Sun T; Zhang MJ; Li WL; Yao Q; Liu W; Ding CM; He ZY; Mao WD; Wang HM; Zhang Y; Zhou XL
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222
[TBL] [Abstract][Full Text] [Related]
10. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
Rong B; Yang S; Li W; Zhang W; Ming Z
World J Surg Oncol; 2012 Aug; 10():170. PubMed ID: 22917490
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland.
Zhu Q; Zang Q; Jiang ZM; Wang W; Cao M; Su GZ; Zhen TC; Zhang XT; Sun NB; Zhao C
Asian Pac J Cancer Prev; 2015; 16(9):4013-8. PubMed ID: 25987078
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
Bao Y; Peng F; Zhou QC; Yu ZH; Li JC; Cheng ZB; Chen L; Hu X; Chen YY; Wang J; Wang Y; Ma HL; Xu ZM; Lu RB; Deng XW; Chen M
Radiother Oncol; 2015 Feb; 114(2):161-6. PubMed ID: 25497558
[TBL] [Abstract][Full Text] [Related]
16. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.
Chen L; Zhu X; Li D; Cai X
J BUON; 2020; 25(6):2643-2649. PubMed ID: 33455108
[TBL] [Abstract][Full Text] [Related]
17. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.
Zhao J; Yu H; Han T; Wang W; Tong W; Zhu X
J BUON; 2019; 24(6):2267-2272. PubMed ID: 31983093
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
20. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
